Global Life Science Ventures
Global Life Science Ventures is a swiss investment fund focusing exclusively on the life sciences sector.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Global Life Science Ventures Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2006 | Intelligent Medical Implants Ltd | Series B | 0 |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 7/2003 | Cyberkinetics | Series A | 9.3M |
| 10/2005 | Nitec Pharma AG | Series A | 10M |
| 3/2007 | Coapt Systems | Series E | 22.6M |
| 12/2009 | Coapt Systems | Debt Financing | 3.7M |
| 3/2004 | CombinatoRx | Series C | 30M |
| 8/2003 | Coley Pharmaceutical Group | Series F | 30M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 12/2005 | NeurogesX | Series D | 20M |
| 9/2005 | Spinal Cord Therapeutics GmbH | Series A | 15.5M |
| 2/1998 | Agromed | Venture Round | 8.2M |
| 3/2004 | Zalicus | Series D | 29.5M |
| 4/2001 | Develogen AG | Series B | 0 |
| 3/2007 | Nitec Pharma AG | Series B | 26M |
| 3/2004 | Agendia | Series A | - |
| 7/2010 | Action Pharma | Series C | 6.3M |
| 1/1998 | Develogen AG | Series A | 3M |
| 2/2004 | NeurogesX | Series C | 35M |
| 1/2017 | Binx Health | Series D | 0 |
| 1/2015 | Binx Health | Series C | 0 |
| 11/2006 | Pieris AG | Series B | 0 |
| 10/2002 | Pieris AG | Series A | 0 |
| 7/2003 | Intercell | Series C | 50M |
| 3/2004 | CareX SA | Series B | 32M |
| 8/2007 | Agendia | Series D | 34M |
| 9/2009 | Agendia | Series E | 23M |
| 1/2004 | FRIZ Biochem | Series B | 3.8M |
| 7/2000 | Cytos | Series B | 32M |
| 1/1999 | Cytos | Series A | 8M |
| 1/2017 | Binx Health | Series D | 0 |
| 1/2015 | Binx Health | Series C | 0 |
| 6/2012 | Santaris Pharma | Venture Round | 0 |
| 7/2010 | Action Pharma | Series C | 0 |
| 12/2009 | Coapt Systems | Debt Financing | 0 |
| 9/2009 | Agendia | Series E | 0 |
| 12/2007 | Santaris Pharma | Series C | 0 |
| 8/2007 | Agendia | Series D | 0 |
| 3/2007 | Coapt Systems | Series E | 0 |
| 3/2007 | Nitec Pharma AG | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
